Adding soy protein to your diet may NOT stop biochemical progression

According to data from a small, randomized, clinical trial published in the Journal of the American Medical Association, daily use of a supplement containing soy protein isolate for 2 years after radical prostatectomy did not reduce risk for biochemical progression of prostate cancer in high-risk patients. … READ MORE …

The management of “hot flashes” for men on ADT

Perhaps the most interesting new data from the annual meeting of the American Society of Clinical Oncology yesterday (Sunday) was a negative result from a four-arm, randomized clinical trial. … READ MORE …

Selenium, vitamin E, soy, and prostate cancer prevention

A new Canadian study just reported in the Journal of Clinical Oncology has failed to find any significant benefit from the use of vitamin E, selenium, and soy protein supplements in the prevention of prostate cancer. … READ MORE …

The genistein saga — all data and no (good) results

The idea that the soy isoflavone known as genistein might prove to be a non-toxic therapeutic agent for the prevention and/or treatment of prostate cancer has now been around for so long that the idea appears to have become a perceived truth in some quarters. … READ MORE …

Soy isoflavones and radiation therapy: a pilot study

Soy isoflavones are known to have antioxidant and anti-inflammatory activities and to sensitize prostate cancer cells to radiation therapy. … READ MORE …

More weekend news reports: March 15, 2009

We have added information about three more recent studies for your weekend reading, dealing with:

  • Soy, diet, and prostate cancer prevention
  • Outcomes of bladder neck preservation during radical prostatectomy
  • A predictive model for chemotherapy outcomes in HRPC patients … READ MORE …

Wednesday’s news reports: February 25, 2009 — Part 2

Our second report today deals with:

  • Soy isoflavone concentration in prostate cancer tissue
  • A new vitamin E ether analog and its activity in the laboratory
  • PSA “half-life” as a prognostic indicator for impact of hormone therapy
  • Apolipoprotein C-I: is it important hormone-refractory prostate cancer?
  • Chemotherapeutic sensitization and its possible impact on taxane therapy … READ MORE …